Zusammenfassung
Die Ejaculatio praecox (EP) ist mit Prävalenzraten von 20–25% die häufigste Sexualstörung des Mannes. Während für die lebenslange EP genetisch determinierte Veränderungen im Serotoninrezeptor-/-transportermechanismus verantwortlich zu sein scheinen, ist die erworbene EP oftmals mit anderen konditionierenden Erkrankungen wie erektile Dysfunktion, Prostatitis oder Schilddrüsenstörungen assoziiert. Die EP ist gekennzeichnet durch eine kurze intravaginale Ejakulationslatenzzeit (IELT) von <1–2 min, eine mangelnde Kontrolle über die Ejakulation, einen hohen persönlichen Leidensdruck sowie partnerschaftliche Probleme. Die Therapie der EP unterteilt sich in sexualtherapeutische Ansätze sowie in medikamentöse Therapiemöglichkeiten, wobei hier die orale Therapie mit selektiven Serotoninwiederaufnahmehemmern (SSRI), mit Dapoxetin als dem ersten für die EP zugelassenen Medikament und die Lokaltherapie mit Lidocain/Prilocain im Vordergrund stehen.
Abstract
With prevalence rates of 20%–25% premature ejaculation (PE) represents the most frequent sexual dysfunction in men. Whereas genetically determined changes in the serotonin receptor-/transporter mechanism seem to be responsible for lifelong PE, acquired PE is often associated with other conditioning diseases such as erectile dysfunction, prostatitis or thyroid dysfunctions. Typical features of PE are a short intravaginal ejaculatory latency time (IELT) <1–2 min, lack of control over ejaculation, personal distress and partner problems. Treatment of PE subdivides into sexual therapy as well as drug therapy. Among the medications considered for PE, oral therapy with selective serotonin re-uptake inhibitors (SSRI), Dapoxetine (the first officially approved medication for PE) and topical therapy with lidocaine/prilocaine-containing medications are given priority.
Literatur
Althof SE, Rosen R, Symonds T et al (2006) Development and validation of a new questionnaire to assess sexual satisfaction, control and distress associated with premature ejaculation. J Sex Med 3:465–475
Buvat J, Tesfaye F, Rothman M et al (2009) Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur Urol 55:957–968
De Amicis LA, Goldberg DC, LoPiccolo J et al (1985) Clinical follow-up of couples treated for sexual dysfunction. Arch Sex Behav 14(6):467–489
Dinsmore W, Wyllie MG (2009) PSD 502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min. before intercourse in men with premature ejaculation: results of a phase III, multicentre, double-blind, placebo-controlled study. BJU Int 103:940–949
Giuliano F, Clément P (2006) Serotonin and premature ejaculation: from physiology to patient management. Eur Urol 50:454–466
Giuliano F, Patrick DL, Porst H et al for the 3004 Study Group (2008) Premature ejaculation: results form a five country European observational study. Eur Urol 53:1048–1057
Jannini EA, Caros E, Pepe M, Lombardo F (2006) Update on pathophysiology of premature ejaculation: the basis for new pharmacological treatments. Eur Urol EAU EBU Update Series 4:141–149
Janssen PKC, Bakker SC, Réthlevy J et al (2009) Serotonin transporter promoter region (5-httlpr) polymorphism is associated with the intravaginal ejaculation latency time in Dutch men with lifelong premature ejaculation. J Sex Med 6:276–84
Jearn P, Santtila P, Johansson A et al (2009) Evidence for a genetic etiology to ejaculatory dysfunction. Int J Impot Res 21:62–67
Lindau ST, Schumm LP, Laumann EO et al (2007) A study of sexuality and health among older adults in the United States. N Engl J Med 357:762–774
McMahon CG, Abdo C, Incrocci L et al (2004) Disorders of orgasm and ejaculation in men. In Sexual medicine: Sexual dysfunctions in men and women. 2nd International Consultation on Sexual Dysfunctions, Paris
McMahon CG, Althof S, Waldinger M, Porst H et al (2008) An evidence-based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine (ISSM) Ad Hoc Committee For The Definition of Premature Ejaculation. J Sex Med 5:1590–1606
McMahon CG (2008) The DSM-IV-TR definition of premature ejaculation and its impact upon the results of epidemiological studies. Eur Urol 53:887–889
Porst H, Montorsi F, Rosen R et al (2007) The Premature Ejaculation Prevalence and Attitudes (PEPA) Survey: Prevalence, comorbidities and professional help-seeking. Eur Urol 51:816–824
Pryor JL, Althof SE, Steidle C et al (2006) Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomized controlled trials. Lancet 368:929–937
Rosen RC, McMahon CG, Niederberger C et al (2007) Correlates to the diagnosis of premature ejaculation: results from a large observational study of men and their partners. J Urol 177:1059–1064
Rowland DL, Patrick DL, Rothman M, Gagnon DD (2007) The psychological burden of premature ejaculation. J Sex Med 177:1065–1070
Sadeghi-Nejad H, Watson R (2008) Premature ejaculation: current medical treatment and directions. J Sex Med 5:1037–1050
Steggall MJ, Fowler CG, Pryce A (2008) Combination therapy for premature ejaculation: results of a small-scale study. Sex Relationship Ther 23:365–376
Waldinger MD (2007) Premature ejaculation. Definition and drug treatment. Drugs 67(4):547–568
Waldinger MD, Zwinderman AH, Oliver B, Schweitzer DK (2005) Proposal fo a definition of lifelong premature ejaculation based on epidemiological stopwatch data. J Sex Med 2:498–507
Interessenkonflikt
Der korrespondierende Autor weist auf folgende Beziehungen hin: Der Autor ist Prüfarzt für folgende Firmen: Eli-Lilly Corp., USA; Johnson & Johnson, USA; Janssen-Cilag, Deutschland; Bayer Healthcare. Der Autor ist Consultant für folgende Firmen: Eli-Lilly Corp., USA; Johnson & Johnson, USA; Janssen-Cilag, Deutschland; Plethora Solutions, UK; Pfizer, Deutschland.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Porst, H. Der vorzeitige Samenerguss (Ejaculatio praecox). Urologe 48, 663–674 (2009). https://doi.org/10.1007/s00120-009-2019-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-009-2019-z